IL6 and rheumatoid arthritis: Tocilizumab and sarilumab, two monoclonal antibodies directed against the receptor of IL-6, showed to be efficacious for the treatment of patients with RA [49,50], whereas they were not effective in AS [51] and were not tested in PsA.